CLARESSA ROSACINA: Open Payments
NPI 1205236718 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,945 in 66 payments from 31 companies in 2025. Trend: 2023 $3,409 · 2024 $2,780 · 2025 $1,945
Food & beverage: $1,775Education: $170
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 9 | $200 |
| US Oncology Corporate, Inc. | 1 | $174 |
| AstraZeneca Pharmaceuticals LP | 7 | $170 |
| BeiGene USA, Inc. | 1 | $154 |
| Merck Sharp & Dohme LLC | 6 | $139 |
| Incyte Corporation | 1 | $95 |
| Celgene Corporation | 4 | $83 |
| Janssen Biotech, Inc. | 4 | $82 |
| ABBVIE INC. | 4 | $80 |
| SEAGEN INC. | 1 | $75 |
Products named: BRUKINSA, KEYTRUDA, ENHERTU, Fabhalta, KISQALI, Lenvima, VENCLEXTA, OJJAARA.
Industry payments across TX — which companies pay providers there.
